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Abstract
Diabetes is a recognized risk factor for cardiovascular diseases and heart failure. Diabetic 
cardiovascular dysfunction also underscores the development of diabetic retinopathy, nephropathy 
and neuropathy. Despite the broad availability of antidiabetic therapy, glycaemic control still 
remains a major challenge in the management of diabetic patients. Hyperglycaemia triggers 
formation of advanced glycosylation end products(AGEs), activates protein kinase C, enhances 
polyol pathway, glucose autoxidation, which coupled with elevated levels of free fatty acids, and 
leptin have been implicated in increased generation of superoxide anion by mitochondria, NADPH 
oxidases and xanthine oxidoreductase in diabetic vasculature and myocardium. Superoxide anion 
interacts with nitric oxide forming the potent toxin peroxynitrite via diffusion limited reaction, 
which in concert with other oxidants triggers activation of stress kinases, endoplasmic reticulum 
stress, mitochondrial and poly(ADP-ribose) polymerase 1-dependent cell death, dysregulates 
autophagy/mitophagy, inactivates key proteins involved in myocardial calcium handling/
contractility and antioxidant defense, activates matrix metalloproteinases and redox-dependent 
pro-inflammatory transcription factors (e.g. nuclear factor kappaB) promoting inflammation, 
AGEs formation, eventually culminating in myocardial dysfunction, remodeling and heart failure. 
Understanding the complex interplay of oxidative/nitrosative stress with pro-inflammatory, 
metabolic and cell death pathways is critical to devise novel targeted therapies for diabetic 
cardiomyopathy, which will be overviewed in this brief synopsis.
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1. Introduction
Incidence of metabolic diseases, especially of obesity and type II diabetes is constantly 
growing worldwide. Diabetes is a well-recognized risk factor for cardiovascular diseases 
and heart failure [1]. The term of diabetic cardiomyopathy has been introduced by Rubler et 
al. back in 1972 [2]. Later the Framingham Heart Study has also demonstrated that the 
occurrence of heart failure in male and female diabetics is twice and five times more 
common, respectively, compared to age-matched control subjects [3]. Similar cross-
sectional studies confirmed increased risk for heart failure development in diabetics, even 
when corrected for other confounding variables such as coronary artery disease, 
hypercholesterolemia, hypertension, and obesity [4-7]. Notably, the higher occurrence of 
biventricular dysfunction and cardiomyopathy in diabetics is also suggestive of the fact that 
diabetes is an independent risk factor or cause of cardiomyopathy [7-9].
Although it is established that multiple factors may collectively contribute to the 
development and progression of diabetic cardiomyopathy (e.g. hyperglycaemia, insulin 
resistance, increased fatty acid metabolism, microcirculatory changes, sympathetic 
dysfunction, myocardial inflammation, remodelling and fibrosis), the exact molecular 
mechanisms that trigger and fuel these major pathological processes are not entirely clear 
(Figure 1).
Accumulating recent evidence suggests that the complex interplay of oxidative, nitrosative 
and nitrative stress [10-12] with major proinflammatory, metabolic[13] and cell death 
pathways [14-17] play an essential role in the development of complex biochemical[18, 19], 
mechanical, and structural alterations associated with diabetic cardiomyopathy[8, 20, 21], 
which will be overviewed in this brief synopsis.
2. Oxidative, nitrosative and nitrative stress in diabetic cardiomyopathy
Oxidative and subsequent nitrosative damage of the myocardium and vasculature have been 
described as major primary mechanisms leading to pathologic alterations associated with 
diabetic cardiovascular complications [22-29]. Factors such as hyperglycaemia, glucose 
autoxidation, accumulation of advanced glycosylation end products (AGEs), enhanced 
receptor for advanced glycation end product (RAGE) and angiotensin II receptor type 1 
(AT1R) signaling, elevated levels of free fatty acids and leptin, have been reported to 
contribute to increased production of reactive oxygen and nitrogen species production (ROS/
RNS) in diabetic vessels and myocardium [22, 24], among others. In spite of the broad 
availability of antidiabetic therapy, glycaemic control still remains a major challenge in the 
management of diabetic patients [30]. Inadequate glycaemic control likely accounts for the 
high prevalence of diabetic complications, since high glucose or fluctuating glucose levels 
[31] can induce acute oxidative stress that might be a critical factor in the initiation of 
pathologic alterations eventually leading to development of diabetic cardiomyopathy [16, 
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24]. Oxidative protein modifications play a pivotal role in the development of diabetic 
myocardial dysfunction. Oxidation of proteins involved in contractility, excitation-
contraction coupling, protein folding, antioxidant defence, metabolism (mainly fatty acid 
and glucose), and Ca2+ handling have been reported in diabetic hearts (see Table 1.). 
Oxidative modification may result in potentially harmful events including dissociation of 
catalytic subunits of enzymes, local or global unfolding, aggregation or fragmentation. 
Proteins can be oxidized directly by ROS, or by products of secondary oxidation reactions 
formed during lipid peroxidation (e.g., malondialdehyde or 4-hydroxynonenal). Moreover, 
oxidative protein modifications may also occur by reactive sugars in glycation or 
glycoxidation reactions [32]. Depending on the amount of modified proteins and the extent 
of oxidation, different degradation mechanisms are activated. Mildly oxidized proteins are 
broken down primarily by the proteasome, while heavily oxidized proteins (potentially 
forming aggregates) are degraded by the endosomal-lysosomal pathway thereafter [33]. 
Thus, an increase in oxidative stress might produce substrates that fuel autophagic protein 
degradation, at least in the first stages of oxidative injury [34]. In addition, certain proteins 
involved in autophagosome formation and maturation (Atg4, LC3-II) require oxidative 
posttranslational modifications [35, 36], thus, activity of these proteins are also strongly 
influenced by their redox status [35]. However, the accumulation of oxidized and nitrated 
proteins and lipids suggest abrogated autophagic processes in diabetic cardiomyopathy that 
may significantly contribute to myocardial dysfunction.
Several cellular and subcellular sources were described that may account for enhanced ROS 
production in diabetic cardiovascular system and at other sites of diabetic complications 
(e.g. in the retina and kidneys) (Figure 2). This list includes nicotinamide adenine 
dinucleotide phosphate oxidases (NADPH oxidases) [37-39], xanthine oxidase/
oxidoreductase (XO)[40, 41], enzymes of the arachidonic acid cascade (cyclooxygenase and 
lypoxygenase enzymes), microsomal enzymes, the uncoupled nitric oxide synthases (NOS) 
[10], and the mitochondrial respiratory chain[24]. Among these, increased mitochondrial 
ROS generation initially was considered to represent the primary source of high glucose-
induced oxidative stress in several tissues and cell types, including cardiomyocytes [24, 37, 
42] and endothelial cells [43, 44]. Luo et al. recently showed, that mitochondrial oxidants 
significantly contribute to the oxidation of the multifunctional enzyme, Ca2+/calmodulin-
dependent protein kinase II (CaMKII) [45]. Diabetic mice treated with a mitochondria-
targeted antioxidant, MitoTEMPO, showed reduced levels of oxidized-CaMKII, 
subsequently with preserved heart rates, and improved survival after myocardial 
infarction[45]. Mitoquinone, a mitochondrially targeted ubiquinone that can act as an 
antioxidant, also improves cardiac dysfunction [46] and activates autophagy in an Nrf2-
dependent manner in a non-cardiac system [47], suggesting an interaction between 
mitochondrial redox balance and protein quality control mechanisms, such as autophagy.
There is also evidence for increased production of ROS from non-mitochondrial sources. 
NADPH oxidases (NOX) are unique enzymes that may be responsible for large amounts of 
superoxide and hydrogen peroxide (H2O2) production under various pathological conditions. 
Activity or expression of various NOX isoenzymes (that are involved in superoxide or H2O2 
generation, has been found to be significantly higher in the heart with metabolic 
derangements such as diabetes [37-39, 48, 49] and hypercholesterolemia [50]. The increased 
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activity and expression of NOX4 in the diabetic heart [49] is therapeutically targetable, and 
NOX4 inhibitors are indeed in preclinical development for various cardiovascular 
indications [51]. Diabetes induced increase in NADPH activity is further accentuated by the 
increased production of NADPH by glucose-6-phosphate dehydrogenase, as it was described 
in the heart and aorta of Zucker diabetic fatty rats [52]. Elevated concentration of hydrogen 
peroxide has been shown to modulate autophagy by several mechanisms. For example, 
H2O2, activates the LKB1/AMPK pathway which leads to inhibition of the mTORC1 
complex and induced autophagy [53]. NOX4-mediated production of hydrogen peroxide 
also induces autophagy in human umbilical vein endothelial cells [54] and in 
cardiomyocytes [55] after induction of endoplasmic reticulum stress. Although, it is 
plausible that excessive amounts of ROS might incapacitate certain players of autophagy. 
Vascular NADPH oxidase is also an important downstream target of angiotensin II, which 
has been proposed to play a pivotal pathological role in the development and progression of 
diabetic cardiovascular [56-59] and other diabetic complications. This is supported by 
convincing evidence obtained from preclinical rodent models of STZ (streptozotocin) -
induced type 1 diabetes, as well as from human myocardial biopsy specimens, suggesting 
that the renin-angiotensin system is up-regulated in diabetes and angiotensin II locally 
through AT1R, which is overexpressed in diabetic hearts or in cardiomyocytes exposed to 
high glucose, importantly contributes to the development of diabetic cardiomyopathy [38, 
57-60]. The beneficial effects of AT1R blockade in diabetic hearts involve, but are not 
limited to, the attenuation of myocardial NADPH oxidase-dependent (such as p47phox) 
ROS generation, inflammation, cell death, fibrosis, and contractile dysfunction [57-60]. AT1 
receptor blockade also prevents glucose-induced cardiac dysfunction directly in ventricular 
myocytes via attenuating the AT1-NADPH oxidase signaling [61]. Consistently with the 
important pathological role of NADPH oxidases-derived ROS generation in diabetic hearts, 
apocynin (a putative non-specific NADPH oxidase inhibitor) not only attenuated the 
enhanced superoxide generation in diabetic hearts, but also improved the diabetes-associated 
cardiac dysfunction in type I diabetic mice[39].
Increased activation of another ROS generating enzyme, the XO, has also been shown in 
different organs [62] of diabetic rats or mice, including in the heart [41]. Conversely, 
inhibition of XO by allopurinol significantly attenuated most pathological features of 
diabetic cardiomyopathy (e.g. myocardial ROS/RNS generation, iNOS expression, cell 
death, and fibrosis) and improved both systolic and diastolic dysfunctions in type I diabetic 
mouse[41] or rat [63] hearts. Importantly, there is also current evidence, coupled with 
numerous previous studies[40], for the beneficial cardiac effects of allopurinol in humans 
[64]. Rekhraj at al. recently described, that in patient with ischemic heart disease, high dose 
off allopurinol was capable to reduce left ventricular muscle mass and improve the 
symptoms of the disease[65].
A substantial amount of experimental evidence suggests that there is reduced nitric oxide 
(NO) availability in diabetic tissues. Different mechanisms have been proposed to be 
responsible for the diabetes-induced dysfunction of NO production, bioavailability and/or 
signaling. A generally accepted mechanism is the alterations in nitric oxide synthases 
(NOS), particularly in its endothelial isoform (eNOS), function [10, 66]. The composition of 
the eNOS complex is critical for the relative formation of NO or superoxide. The 
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mechanisms by which eNOS dysfunction develops remain elusive, however, a decrease in 
the dimer to monomer eNOS ratio within the myocardium of diabetic animals has been 
reported [67]. Monomerization i.e. uncoupling of NOS results in increased oxidative stress 
and decreased NO bioavailability (since uncoupled NOS generates superoxide anion instead 
of NO), which has been implicated in the pathophysiology of numerous cardiovascular 
diseases. Accordingly, eNOS uncoupling has also been reported in diabetic hearts, while 
administration of the tetrahydrobiopterin precursor, sepiapterin inhibited uncoupling of NOS 
and improved LV function [68]. Similarly, ascorbic acid or N-acetyl-cystein is also capable 
to increase BH4/BH2 ratio and prevent NOS uncoupling in the diabetic heart [69]. In 
addition to uncoupling the major cardiac NOS isoforms, iNOS and eNOS expression has 
been shown to be increased (particularly iNOS) in the diabetic hearts [37, 38, 70, 71]. The 
increase in NOS expression in the diabetic heart is associated with an increase in lipid 
peroxidation and 3-nitrotyrosine formation (marker of peroxynitrite generation and nitrative 
stress), which might be related to the uncoupled and monomer state of the enzyme, which 
most likely produces superoxide instead of NO, as well as triggers the formation of 
peroxynitrite. Interestingly, peroxynitrite itself also causes NOS un-coupling by selectively 
targeting and disrupting caveolae-NOS interaction [72].
The rapid diffusion-limited reaction of superoxide with NO indeed forms peroxynitrite, a 
very strong cytotoxic oxidant, which attacks and damages various biomolecules via multiple 
mechanisms [10]. In agreement with these, inhibition of NOS activity (by L-NAME or L-
NMMA) improves myocardial performance in diabetic hearts, suggesting that the increased 
production of superoxide and peroxynitrite rather than NO is a major contributor of 
suppressed contractile performance in diabetes [39, 66, 73, 74]. NO and peroxynitrite has a 
very complex relation to autophagy. Nitric oxide donors have been shown to decreased 
autophagy in HeLa cells, which has been confirmed by the overexpression of eNOS [75]. 
Although, LPS-induced up-regulation of NOS izoenzymes were followed by an accelerated 
autophagy in HL-1 cells and in mice [76]. Since LPS induces the production of not only NO, 
but peroxynitrite, these seemingly opposing results can be explained. It is further evidenced 
by other studies, where peroxynitrite exerted inhibitory effects on autophagy. For example, 
peroxynitrite induced autophagy in endothelial cells and increased LC3-II protein [77]. 
These data well demonstrate that sub-physiological NO levels and nitrosative/nitrative stress 
which are characteristic to diabetes, might facilitate autophagic processes in the heart, 
however, direct observations are yet to be made. Peroxynitrite formation and consequent 
protein nitration (nitrative stress) have been suggested to play a central role in the 
development of cardiovascular dysfunction associated with diabetes, as well as in the 
development of diabetic retinopathy, nephropathy and neuropathy. Peroxynitrite in hearts 
not only promotes apoptotic or necrotic cell death in cardiomyocytes and endothelial cells 
via activation of stress signaling pathways (e.g. mitogen activated protein kinases (MAPKs) 
and poly ADP ribose polymerase 1 (PARP-1)-dependent pathways), but also induces 
nitration and consequent inactivation of key proteins involved in intracellular calcium 
cycling, energy homeostasis, antioxidant defense, and myocardial contractility (see Table 2.) 
[10]. Peroxynitrite, in concert with other oxidant may also activate matrix 
metalloproteinases (MMPs) in the failing hearts to promote pathological remodeling [23, 37, 
78] and may impair the NO-soluble guanylate cyclase signaling pathway rendering NO to 
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unable to activate its primary protective signaling machinery [79, 80]. Furthermore, 
peroxynitrite decomposition catalysts have been shown to restore the normal contractile 
phenotype of high glucose treated cardiomyocytes and attenuate cardiac dysfunction in 
diabetic hearts [74]. The importance of peroxynitrite has also been shown in diabetic 
patients. Increased serum and/or vascular 3-nitrotyrosine levels were positively correlated 
with increased blood pressure, and or endothelial dysfunction in diabetic patients [29, 81]. 
The persistently increased myocardial oxidative and nitrative stress in diabetic hearts 
eventually also leads to dysfunction of important antioxidant defense mechanisms [10] (e.g. 
inactivation of important antioxidant enzymes such as superoxide dismutases and catalase, 
depletion of endogenous antioxidants (e.g. metallothionein, glutathione) [37, 82-84]) and 
dysregulation of important redox-dependent transcription factors (e.g. NFE2L2 nuclear 
factor, erythroid 2-like 2 (Nrf2)) [85, 86], among others. Increased oxidative and nitrative 
stress in diabetes may also promote oxidation and/or nitration of various insulin receptors in 
peripheral tissues, which may contribute to the development of insulin resistance [87].
Hyperglycemia and/or hyperglycemia-induced ROS has been reported to increase 
accumulation of products of nonenzymatic glycation/oxidation of proteins/lipids (AGE) and 
enhanced the expression of their receptor (RAGE) in cardiovascular tissues, which thought 
to play a key role in the development and progression of cardiovascular complications of 
diabetes [88, 89]. Accumulation of AGEs and increased expression of RAGE have been 
associated with diabetes-induced dysfunction and structural alterations in hearts of type 1 
diabetic rodents [88, 89]. Furthermore, in diabetic heart failure patients with reduced LV 
ejection fraction, the accumulation of AGEs and fibrosis appear to contribute to the 
increased diastolic stiffness, but not in patients with normal LV ejection fraction, where the 
increased cardiomyocyte resting tension is responsible for this phenomenon[90].
3. Autophagy and cell death mechanisms in diabetic cardiomyopathy
It has extensively been documented that increased oxidative and nitrative stress in diabetic 
hearts may trigger activation of stress signalling pathways facilitating apoptosis in 
cardiomyocytes and endothelial cells [14]. However, recent evidence also suggests that in 
addition to apoptosis, other processes such as autophagy, mitophagy and PARP-dependent 
cell death pathways may also play an important role in controlling the cell demise during the 
course of cardiovascular disease[91] and diabetic cardiomyopathy [17], which will be 
discussed in the following part.
Autophagy is a cellular housekeeping process that is essential for removal of damaged or 
unwanted organelles, protein and lipid aggregates. It is a dynamic process which is tightly 
regulated by the availability of nutrients and the metabolic balance of the cell, and functional 
autophagy is indispensable for cellular survival in low-energy conditions [92]. Since in 
diabetes, where oxidative stress, protein- and lipid oxidation are elevated and cellular energy 
balance is disturbed, functional autophagy might have even higher importance in the 
maintenance of cardiac cellular integrity. In the heart, constitutive autophagy is a 
homeostatic mechanism for maintaining cardiac structure and function [93], while disruption 
of autophagy leads to heart failure [94]. Interestingly, in healthy animals, autophagy seems 
to be higher in males than in females suggesting that the male heart has a major constitutive 
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autophagy [95]. This gender difference may elucidate the observation of the Framingham 
Heart Study showing markedly increased occurrence of diabetic cardiomyopathy in females 
[3, 96]. Autophagy is suppressed at high glucose concentrations, such as present in diabetes, 
which might be associated with the development of diabetic cardiomyopathy [97]. In 
addition, the diabetic heart is characterized by excessive fatty acid uptake and oxidation, 
resulting in accumulation of toxic lipid intermediates (long-chain acyl-CoA, diacylglycerol, 
ceramides), known as lipotoxicity. Cardiac lipotoxicity contributes to insulin resistance, 
impairment of mitochondrial function, CM hypertrophy, and apoptosis, which may 
ultimately lead to left ventricular remodelling of the heart [98].
Elevated oxidative stress, apoptosis, inflammation, and ER stress by increased production of 
monocyte chemoatractic protein-1 (MCP-1) is suspected to contribute to the disruption of 
cardiac autophagy in diabetes [97, 99-101] Several upstream signalling pathways of 
autophagy are altered in diabetes or metabolic syndrome as well [102]. The mammalian 
target of rapamycin (mTOR) pathway, a negative regulator of autophagy is blunted in obese, 
hyperlipidemic rats fed a high cholesterol-high fructose diet showing most characteristics of 
type II diabetes [103]. Also, activity of AMP-activated protein kinase (AMPK) is reduced in 
high glucose conditions, leading to disturbed autophagy[104]. Although the majority of 
reports agree on the attenuation of the autophagy in diabetes, not all studies are equivocal 
(possibly due to the different experimental models used). For example, in a fructose-fed 
mouse model, induction of autophagy has been described[105], and milk fat-based chow 
blunted cardiac autophagy and facilitated cardiomyopathy more efficiently than a lard-based 
chow [106]. Further complicating the picture is the discrepancy that oxidative stress is 
elevated in diabetes, which is supposed to induce autophagy, however, the majority of 
studies evidence quite the opposite. This phenomenon and the lack of any direct evidence 
from diabetic patients warrant further investigations on the status of cardiac autophagy in 
disease models relevant to human pathological conditions.
Aiming to restore pathological cardiac consequences of diabetes modulation of autophagy 
has been attempted by different tools. Chronic activation of AMPK (therefore autophagy) by 
metformin or overexpression of ATG7 reduced cardiomyocyte apoptosis, cardiac fibrosis, 
and improved myocardial functions in streptozotocin (STZ)-induced diabetic mice [104]. 
Overexpression of hem oxygenase-1 in STZ-treated mice also induced autophagy, reduced 
oxidative stress and inflammation and prevented cardiac dysfunction [97]. In a recent report, 
inhibition of mTOR signalling by the overexpression of PRAS40 prevented the development 
of cardiomyopathy in high-fat diet-fed mice [107]. Furthermore, it was also demonstrated 
that disturbed autophagy undermine the benefit of exercise in protection against high-fat-
diet-induced glucose intolerance [108]. However, a few papers disagree with this 
conclusion. Suppression of autophagy prevented apoptosis in neonatal and adult 
cardiomyocytes in extremely high glucose conditions resembling to uncontrolled diabetes 
[109]. Furthermore, overexpression of beclin-1, an inducer of autophagy, worsened cardiac 
function and enhanced apoptosis in STZ-treated mice, while cardiac damage by STZ-
induced diabetes was blunted in beclin-1+/− mice [110]. In summary, although the 
usefulness of induction of autophagy in diabetes is still a controversial issue, the majority of 
reports implicate that the restoration of cellular energy household, induction of antioxidant 
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systems and reduction of the detrimental protein synthesis by the modulation of autophagy-
related pathways might serve as therapeutic targets in the treatment or prevention of diabetes 
and its cardiac complications, once we better understand these processes.
ROS and RNS under pathological conditions may also lead to oxidative DNA injury and 
overactivation of the nuclear enzyme poly (ADP-ribose) polymerase 1 (PARP-1), the 
predominant isoform of the PARP enzyme family, which normally participates in the 
regulation of DNA repair, cell death, metabolism, and inflammatory responses [111]. 
Following binding to damaged DNA, PARP-1 forms homodimers and catalyzes the 
cleavage of its substrate NAD+ into nicotinamide and ADP-ribose resulting in formation of 
longbranches of ADP-ribose polymers on target proteins such as histones and PARP-1 itself, 
which results in cellular energetic depletion, mitochondrial dysfunction, and ultimately 
necrosis. Numerous transcription factors involved in controlling inflammation such as 
NFkB, and various signaling molecules have also been shown to become poly(ADP-
ribosylated) by PARP-1 [112]. Thus, overactivation of PARP-1 due to ROS/RNS formation 
not only promotes cell death by ATP and NAD+ depletion, but also stimulates 
proinflammatory mediator production. PARP inhibitors exerted marked tissue protective and 
antiinflammatory effects in preclinical models of ischemia-reperfusion injury, endothelial 
and cardiac dysfunction, circulatory shock, heart failure and diabetic complications [16, 
112]. More excitingly several recent studies have also suggested that PARP-1 and PARP-2 
(a minor isoform of the PARP enzyme family) are involved in regulation of mitochondrial 
function/biogenesis, and adipogenesis in various organ systems [113, 114], including in the 
liver, via modulation of NAD+ levels and consequently sirtuin 1 activity [111, 115]. 
Specifically, PARP inhibitors in rodent models of type I diabetes were very effective in 
improving endothelial [116, 117] and cardiac function [118], and the PARP activation from 
skin biopsies in microvessels positively correlated with the degree of endothelial 
dysfunction in prediabetic and diabetic human subjects [29]. PARP inhibition also prevented 
the hyperglycemia-induced pathological activation of PKC isoforms, hexosaminase pathway 
flux, and AGE formation in vitro, suggesting its key role in regulating pathological 
processes promoting the development of all major diabetic complications [16] .
4. Inflammation in diabetic cardiomyopathy
Tschope et al. found using a STZ-induced rat model of type I diabetes that the diabetic 
cardiomyopathy was characterized by significant increases in myocardial intercellular 
adhesion molecule 1 and vascular cell adhesion molecule 1 (ICAM-1 and VCAM-1) 
expressions, as well as of beta2-leukocyte-integrins+ (CD18+, CD11a+, CD11b+) and 
cytokine tumor necrosis factor alpha (TNF-α) and interleukin 1 beta (IL-1β))-expressing 
infiltrating immune cells. And these pro-inflammatory changes were positively correlated 
with oxidative stress and decline of left ventricular function [119]. Interestingly, transgenic 
activation of the kallikrein-kinin system inhibited intramyocardial inflammation, endothelial 
dysfunction and oxidative stress in diabetic hearts [119]. They found that the AT-1 receptor 
antagonists irbesartan attenuated cardiac failure by decreasing cardiac inflammation (IL1β, 
TNFα, and TGFβ levels) and normalizing MMP activity, leading to attenuated cardiac 
fibrosis in STZ-induced diabetic cardiomyopathy [57]. Using mouse or rat models of type I 
diabetes they also demonstrated that neutralization of TNFα [120] or genetic deletion of 
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kinin receptor B [121] attenuated the development of experimental diabetic cardiomyopathy 
associated with a reduction of intramyocardial inflammation and cardiac fibrosis. They also 
showed that inhibition of p38 mitogen-activated protein kinase attenuated left ventricular 
dysfunction by decreasing the level of myocardial pro-inflammatory cardiac cytokines in a 
mouse model of diabetes mellitus[122], and more recently they suggested that the STZ-
induced diabetic cardiomyopathy is a robust model for investigating cardiac immune 
response and LV remodeling processes under diabetic conditions [123]. Several studies from 
other groups have also found similar pro-inflammatory changes in the myocardium of 
diabetic rodent hearts [37, 38, 41]. Recently, using type I and II models of diabetes in mice 
several studies have also shown activation of the major pro-inflammatory transcription 
factor nuclear factor kappa B in diabetic hearts[37, 124] or in human cardiomyocytes or 
coronary artery endothelial cells exposed to high glucose concentrations which triggered 
enhanced ROS/RNS generation[37]. Both studies demonstrated that the anti-inflammatory 
compounds used for the treatments by attenuating inflammation also decreased oxidative/
nitrative stress, myocardial cell death, remodeling, and improved diabetes-induced 
contractile dysfunction in rodent hearts [37, 124]. On the other hand, it has been also 
reported that the clinically effective drugs (statins [125], RAAS inhibitors [57], metformin 
[126], and thiazolidinediones [127]) used in the treatment of metabolic syndrome attenuate 
the inflammatory response in diabetes.
Cytokines can attenuate myocyte contractility and viability by various mechanisms. For 
example by formation of peroxynitrite, which was shown to be a major contributor to 
cytokine-induced myocardial contractile failure[128]. Peroxynitrite is also a major trigger of 
apoptosis in cardiomyocytes exposed to various insults in vitro or in vivo [129, 130]. Other 
proposed mechanisms may involve direct action on sarcoplasmic reticulum function and on 
the regulation on the SR calcium ATPase expression and activity by oxidation/nitration [10, 
131]. It is also known, that inflammatory cytokines may regulate the extracellular matrix 
composition and dynamics in the heart, which is a known important determinant of 
myocardial function [132]. In agreement with this, inhibition of TNFα signalling with an 
antibody for 6 weeks attenuated myocardial inflammation and fibrosis in experimental 
diabetes [120].
The role of myocardial cytokine signaling in the regulation of autophagy and protein quality 
control is unknown. In other cell types, autophagosomes are formed in response to a number 
of environmental stimuli, including both host- and pathogen-derived molecules, toll-like 
receptor ligands or various cytokines[133, 134]. In particular, the cytokines IFN-γ, TNF-α, 
IL-1, IL-2, IL-6 and TGF-β have been shown to induce autophagy, while IGF-1, IL-4, IL-10 
and IL-13 have inhibitory effect. In parallel, autophagy itself can regulate expression of 
several cytokines, including IL-1, IL-18, TNF-α, and IFN-γ (for an extensive review see 
[134]).
Recent preclinical and clinical studies have also highlighted the role of endocannabinoids 
(novel lipid mediators) and their G protein coupled cannabinoid receptors (CB1 and CB2 
receptors) in the regulation of food intake, energy balance, and metabolism (for extensive 
review see: [135]). The endocannabinoid system also plays a prominent role in the 
pathology of diabetes and obesity [136, 137]. We recently explored the role of 
Varga et al. Page 9
Biochim Biophys Acta. Author manuscript; available in PMC 2016 February 01.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
endocannabinoids and CB1 receptors in a type I model of diabetic cardiomyopathy. The 
diabetic cardiomyopathy was characterized by myocardial inflammation, increased 
expression of CB1, oxidative/nitrative stress, β-MHC isoenzyme switch, AT1R up-
regulation, myocardial RAGE and AGE expression/accumulation, MAPK activation, cell 
death, and cardiac dysfunction (both systolic and diastolic). Pharmacological inhibition or 
genetic deletion of CB1 receptors was associated with attenuated diabetes-induced 
myocardial inflammation, decreased MAPK activation, oxidative/nitrative stress, β-MHC 
isoenzyme switch, AT1R up-regulation, myocardial RAGE and AGE expression/
accumulation, MAPK activation, and largely diminished cell death and better preservation 
of cardiac function [38]. Recent studies indicate that cannabinoids (especially CB1 agonists) 
may be important inductors of autophagy in preimplantation mouse embryos [138] and in 
human epithelial colorectal adenocarcinoma cells (CaCo2) [139]. Although, the evidences 
outlined here clearly show that inflammation is one of the key therapeutically important 
components associated with diabetic cardiomyopathy, to see if pharmacologic modulation of 
cytokine as well as cannabinoid signalling and thereby autophagy has therapeutic potential, 
further experimental studies are required.
5. Conclusions
Despite our accumulating knowledge based on preclinical reports, the treatment of diabetic 
cardiomyopathy is still largely symptomatic once it fully develops, which inevitably 
progresses to heart failure (see Figure 3 for the progression of diabetic cardiomyopathy to 
heart failure). Therefore, an early diagnosis of this condition and rigorous glycaemic control 
is very important to try to slow down the progression of the disease as much as possible. 
From preclinical and human studies it has become clear that oxidative/nitrative stress and 
inflammation are central components in triggering and driving the pathological processes 
associated with diabetic cardiomyopathy and other cardiovascular complications. However, 
recognizing the largely disappointing results of clinical trials with global antioxidants in 
diabetes, it is essential to keep in mind the necessity of more thorough understanding the 
complex interplay of oxidative/nitrosative stress with pro-inflammatory, metabolic and cell 
death signaling pathways, the specificity of these processes, and their temporal-spatial 
relationship.
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HIGHLIGHTS
• Clinical treatment of diabetic cardiomyopathy is still largely symptomatic
• Oxidative stress and inflammation fuel development of diabetic cardiomyopathy
• Cell death pathways, including autophagy, are dysregulated in diabetic hearts
• Cell death has complex interplay with oxidative stress and inflammation
• These pathways are promising therapeutic targets in the diabetic heart
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Figure 1. Interplay of hyperglycemia and peripheral metabolism in cardiometabolic syndrome in 
mediating diabetic cardiovascular complications
Hyperglycemia may indirectly (via its metabolic consequences) or directly enhance 
diabetes-associated inflammation and ROS generation, promoting tissue injury and the 
development of diabetic cardiovascular and other complications. AT II rec, angiotensin II 
receptor type 1; CNS, central nervous system; PMNs, polymorphonuclear leukocytes; XO, 
xanthine oxidase.
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Figure 2. Interplay of oxidative and nitrosative/nitrative stress with cell death pathways in 
diabetic cardiomyopathy
Hyperglycemia via activation of various pathways shown in the large yellow box increased 
superoxide anion (O2•−) production in cardiovascular cell types. NO and superoxide (O2•−) 
rapidly react to form peroxynitrite (ONOO−) which induces cell injury via enhanced lipid 
peroxidation, inactivation of enzymes and other proteins by oxidation and nitration, and also 
activation of stress signaling, matrix metalloproteinases (MMPs) among others. 
Peroxynitrite also triggers the release of proapoptotic factors such as cytochrome c and 
apoptosis-inducing factor (AIF) from the mitochondria, which mediate caspase-dependent 
and -independent apoptotic cell demise pathways. Autophagy may be beneficial in diabetic 
cardiomyopathy in removal of injured cells, but additional support is required to prove its 
exact role. Peroxynitrite, in concert with other reactive oxidants, causes stand breaks in 
DNA, activating the nuclear enzyme poly(ADP-ribose) polymerase-1 (PARP-1). Mild 
damage of DNA activates the DNA repair machinery, but once excessive oxidative/
nitrosative stress-induced DNA damage occurs, like in diabetes, overactivated PARP 
initiates an energy-consuming cycle by transferring ADP-ribose units from nicotinamide 
adenine dinucleotide (NAD+) to nuclear proteins, resulting in rapid depletion of the 
intracellular NAD+ and ATP pools, slowing the rate of glycolysis and mitochondrial 
respiration, eventually leading to cellular dysfunction and demise. Poly(ADP-ribose) 
glycohydrolase (PARG) degrades poly(ADP-ribose) (PAR) polymers, generating free PAR 
polymer and ADP-ribose. Overactivated PARP also facilitates the activation of NFkB and 
expression of a variety of pro-inflammatory genes leading to increased inflammation and 
associated oxidative stress, thus facilitating the progression of cardiovascular dysfunction 
and heart failure. Via attenuation of the cellular NAD+ levels PARP activation may also 
promote metabolic dysfunction via decreased activity of SIRT-1 in various tissues. In 
addition to these adverse consequences the NO bioavailability and signaling is also impaired 
in diabetic hearts promoting impaired vasorelaxation and enhanced atherogenesis eventually 
facilitating increased cardiovascular inflammation, and lipid deposition in vessels and 
myocardium, functional ischemia and enhanced cardiac injury.
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Figure 3. Progression of diabetic cardiomyopathy: role of oxidative/nitrosative stress, 
inflammation, cell death and remodeling
The mechanisms leading to diabetic cardiomyopathy and failure are complex. Eventually the 
pathological alterations will result in mismatch between the load applied to the heart and the 
energy needed for contraction, leading to mechanoenergic uncoupling. After initial insults 
(episodes of hyperglycemia), secondary mediators such as angiotensin II (AII), 
norepinephrine (NE), endothelin (ET), proinflammatory cytokines [e.g., tumor necrosis 
factor-α (TNF-α) and interleukin 6 and IL1β (IL-6 and IL1β), in concert with oxidative 
stress and peroxynitrite, activate downstream effectors (e.g., PARP-1 or MMPs)], act 
directly on the myocardium or indirectly via changes in hemodynamic loading conditions to 
cause endothelial and myocardial dysfunction, cardiac and vascular remodeling with 
hypertrophy, fibrosis, cardiac dilation, and myocardial necrosis, leading eventually to heart 
failure. The adverse remodeling and increased peripheral resistance further aggravate heart 
failure. MMPs, matrix metalloproteinases; PARP-1, poly(ADP-ribose) polymerase.
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